MP41-12 ASSESSING MOLECULAR HETEROGENEITY OF PROSTATE CANCER BIOPSY SAMPLING: INSIGHTS FROM THE MAST TRIAL

• DOI: 10.1097/01.ju.0001008896.93851.5b.12
• Publication Date: 2024-04-15T21:33:57Z
• Authors: Tarek Ajami; Hui Yu; Yuval Avda; Nachiketh Soodana...; Sandra Gaston; Alan Pollack; Brandon Mahal; Radka Stoyanova; Aleksandr Kryvenko; Mark L. Gonzalgo; Bruno Nahar; Chad Ritch; Dipen J. Parekh; Sanoj Punnen; Sabika Sadiq
• Keywords: Prostate biopsy

You have accessJournal of UrologyProstate Cancer: Markers I (MP41)1 May 2024MP41-12 ASSESSING MOLECULAR HETEROGENEITY OF PROSTATE CANCER BIOPSY SAMPLING: INSIGHTS FROM THE MAST TRIAL Tarek Ajami, Hui Yu, Yuval Avda, Nachiketh Soodana-Prakash, Sandra Gaston, Alan Pollack, Brandon Mahal, Radka Stoyanova, Aleksandr Kryvenko, Mark L. Gonzalgo, Bruno Nahar, Chad Ritch, Dipen J. Parekh, Sanoj Punnen, and Sabika Sadiq AjamiTarek Ajami , YuHui Yu AvdaYuval Avda Soodana-PrakashNachiketh Soodana-Prakash GastonSandra Gaston PollackAlan Pollack MahalBrandon Mahal StoyanovaRadka Stoyanova KryvenkoAleksandr Kryvenko GonzalgoMark Gonzalgo NaharBruno Nahar RitchChad Ritch ParekhDipen Parekh PunnenSanoj Punnen SadiqSabika View All Author Informationhttps://doi.org/10.1097/01.JU.0001008896.93851.5b.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Prostate cancer is heterogeneous multi-focal, biopsy sampling often under-samples the tumor or samples different foci. Such multiple may cause molecular heterogeneity that leads an underestimation risk. Consequently, this impacts treatment decision making management in localized prostate cancer. Herein, we evaluate degree variability genetic alterations, genomic risk between cores with respect method (targeted vs systematic) MRI phenotype (PIRADS score). METHODS: A total 348 from 156 patients Miami selection for Active Surveillance versus Treatment (MAST) trial (NCT02242773) were used study. Across whole time-course, all successful gene expression profiling categorized by mpMRI targeted (110 samples) template (187 sampling. Cores higher Gleason score each group selected. Variation was analyzed across same patients. RESULTS: The Decipher (DGS) statistically unpaired analysis (p=0.02), but no difference paired analysis. Of pathways, there regarding both groups, except E2F transcription factor. did not vary according PIRADS (p=0.6). Angiogenesis pathway, factor G2/M checkpoint pathway highly expressed 5 lesions, whereas estrogen response signaling lower 5. Among 6 disease, DGS comparable lesions (p=0.63). CONCLUSIONS: could lead result better assessment cancer, however, radiologic lesion scoring correlated No differences found GG1 disease scores. In low correlation exist phenotype. Download PPT Source Funding: None © 2024 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e678 Advertisement Copyright & Permissions© Inc.Metrics Information More articles author Expand PDF downloadLoading ...